NIRSEVIMAB

Indication	• Prevention of RSV[1-4]

INTRAMUSCULAR

Presentation
- Prefilled syringe: 50 mg in 0.5 mL
- Prefilled syringe: 100 mg in 1 mL

Dosage[1,5]

*Current gestational age	Current weight	Dose
Less than 8 months	Less than 5 kg	50 mg single dose
	5 kg or more	100 mg single dose

**Current gestational age is the same as postmenstrual age (PMA)*

Preparation
- Visually inspect solution (clear to opalescent and colourless to yellow[1,5,6])
  - Discard if cloudy, discoloured or contains particulate matter[1,5]

Administration
- IM injection into thickest part of the vastus lateralis in the anterolateral thigh (maximum 0.5 mL per site)[1,5,6]
  - If multiple injections into same thigh are necessary, separate injections sites by at least 2.5 cm[7]

Special considerations	• Precautions o Anticoagulation therapy or bleeding disorders (e.g. haemophilia, thrombocytopenia)[1,6], increased risk of injection site haematoma • If 100 mg single dose unavailable, administer 2 x 50 mg single dose • Single dose provides protection for at least 5 months[1,3,5,7] • Consider implementing a local protocol to aid identification of IM injection sites, such as o Left thigh–vitamin K_1 and HBIG o Right thigh–hepatitis B vaccine and nirsevimab
Eligibility and timing of administration	• A non-seasonal (year-round) approach is recommended for Queensland by Queensland Health[8] • Eligibility criteria and timing of administration (including for babies 8 months or more) as identified in current QH guidance o Refer to: *The Queensland Paediatric Respiratory Syncytial Virus Prevention Program: Clinical Guidance for Immunisation Service Providers*[8] • If inpatient in neonatal unit o Individualise assessment[8] o If prolonged admission, recommend administration prior to discharge[8] • If confirmed RSV infection o Defer until asymptomatic[8]
Documentation	• Consent and patient information, as per local protocols • Personal Health Record (immunisation section) o Affix adhesive batch label from prefilled syringe • Australian Immunisation Register
Monitoring	• Post-immunisation observations (as per local protocol)[6] o Injection site for redness and swelling[1,6]
Compatibility	• No information[5,6]
Incompatibility	• Do not mix other vaccines in same syringe[1,6]
Interactions	• Other immunoglobulins (e.g. HBIG)[6] o If administered at the same time, give in alternate thigh[6] • Palivizumab o Do not administer if nirsevimab administered in same season[1,5,8] o If palivizumab previously administered, nirsevimab can be administered after 28 days[8]

Stability[1,5,6]	• Refrigerate 2–8 °C o Do not freeze. Protect from light. Do not shake before use o Can be stored at room temperature for a maximum of 8 hours. Discard if not administered within this time
Side effects	• Integumentary: redness or swelling (injection site)[1,6], rash[1] • Nervous system: fever[6,9] • Rare: hypersensitivity reaction (i.e. anaphylaxis)[1,6,7]
Actions	• Recombinant human IgG long-acting monoclonal antibody against RSV[1,3,4,10] • Provides passive immunity by targeting and altering the RSV surface protein[10] • Prevents fusion of viral and cellular membranes and viral entry into the host cell[10]
Abbreviations	• Current gestational age is the same as *postmenstrual age* (PMA) HBIG: hepatitis B immunoglobulin, IgG: immunoglobulin G, IM: intramuscular, QH: Queensland Health, RSV: respiratory syncytial virus
Keywords	human IgG, IgG, neonatal medicine, neonatal monograph, nirsevimab, passive immunity, respiratory syncytial virus, RSV

The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

References

1. IBM Micromedex®Neofax®. Nirsevimab. [Internet]. Colorado USA: Truven Health Analytics; 2024 [cited 2024 June 3]. Available from: https://www.micromedexsolutions.com/neofax.
2. Turalde-Mapili MWR, Mapili JAL, Turalde CWR, Pagcatipunan MR. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: a systematic review and meta-analysis. Frontiers in Pediatrics 2023;11:1-9. doi:10.3389/fped.2023.1132740.
3. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. The New England Journal of Medicine 2020;383(5):415-25. doi:10.1056/NEJMoa1913556.
4. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. The New England Journal of Medicine 2022;386(9):837-46. doi:10.1056/NEJMoa2110275.
5. Therapeutic Goods Administration (TGA). Nirsevimab (Beyfortus). [Internet]. Canberra: Australian Government; November 2023 [cited 2024 November 27]. Available from: https://www.tga.gov.au.
6. Australian Injectable Drugs Handbook. Nirsevimab. 9th ed. [Internet]. New South Wales: Society of Hospital Pharmacists of Australia (SHPA); May 2024 [cited 2024 June 3]. Available from: https://aidh.hcn.com.au.
7. Australian Government Department of Health and Aged Care. Australian Technical Advisory Group on Immunisation (ATAGI). [Internet]. March 2024 [cited 2024 June 4]:1-6. Available from: https://www.health.gov.au/committees-and-groups/atagi.
8. Queensland Health. The Queensland Paediatric Respiratory Syncytial Virus Prevention Program. Clinical guidance for immunisation service providers [Internet]. 2024 [cited 2024 November 27]. Available from: https://www.health.qld.gov.au.
9. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. The New England Journal of Medicine 2023;389(26):2425-35. doi:10.1056/NEJMoa2309189.
10. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science Translational Medicine 2017;9(388). doi:10.1126/scitranslmed.aaj1928.

Document history

ID number	Effective	Review	Summary of updates
NMedQ24.121-V1-R29	19/09/2024	19/09/2029	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)
NMedQ24.121-V2-R29	21/01/2025	19/09/2029	Amended: non-seasonal approach for Queensland incorporated Amended: eligibility criteria aligned with QH Paediatric RSV guidance Updated: references and minor formatting

QR code